8-KEarnings & ResultsExhibits & Filings

AMGEN INC 8-K Report, Financial Results (Jul 26, 2012)

Filed July 26, 2012For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K on July 26, 2012, primarily to report its unaudited financial results for the second quarter and the first half of 2012, ending June 30, 2012. The filing focuses heavily on the company's use of non-GAAP financial measures to provide investors with supplemental information beyond standard U.S. Generally Accepted Accounting Principles (GAAP). These adjustments are intended to offer a clearer view of ongoing operational performance by excluding items such as the impact of stock option expensing, acquisition-related costs, facility transaction expenses, intangible asset amortization, cost-saving initiatives, contingent consideration, legal expenses, and non-cash interest expenses related to convertible notes. Investors should note that Amgen provided these non-GAAP measures to facilitate comparisons across periods, particularly before and after certain expenses were incurred, or to treat acquired intellectual property similarly to internally developed assets. The company also reported Free Cash Flow (FCF) as a non-GAAP measure, calculated as cash flow from operations less capital expenditures, to offer a further perspective on liquidity. The detailed breakdown of these adjustments highlights Amgen's efforts to present a more normalized view of its financial condition and operational profitability.

Key Highlights

  • 1Amgen reported its unaudited financial results for the second quarter and first half of 2012 as of June 30, 2012.
  • 2The company utilized non-GAAP financial measures extensively, providing adjusted figures for various financial statement line items and earnings per share.
  • 3Key adjustments to GAAP measures included excluding stock option expensing, acquisition-related expenses, and expenses related to a transaction with Boehringer Ingelheim (BI) involving its Fremont manufacturing facility.
  • 4Amgen also excluded the amortization of acquired product technology rights, cost-saving initiatives, contingent consideration costs, legal expenses, and non-cash interest expense on convertible notes from its adjusted financial results.
  • 5The company presented Free Cash Flow (FCF) as a non-GAAP metric, defining it as cash flow from operations minus capital expenditures.
  • 6These non-GAAP measures were presented to offer investors supplemental insights and facilitate comparisons across different reporting periods, especially around the incurrence of specific expenses or the existence of convertible notes.
  • 7The report includes a press release dated July 26, 2012, as Exhibit 99.1, which contains the detailed financial results and reconciliations.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report Amgen Inc.'s unaudited financial results for the second quarter and the first six months of 2012, ending on June 30, 2012. It includes a detailed press release that outlines these results and the company's financial position.

Amgen is using non-GAAP financial measures to provide investors with supplemental information that it believes offers a more meaningful view of its operational performance and financial condition. These measures are adjusted to exclude certain items that management believes do not reflect the company's core ongoing business activities, such as specific transaction costs, stock option expensing, acquisition-related expenses, and non-cash charges. The company aims to facilitate comparisons between different reporting periods and provide insights into profitability and liquidity.

Key items excluded from Amgen's non-GAAP financial measures include the impact of expensing stock options, expenses related to the Boehringer Ingelheim (BI) transaction (including accelerated depreciation), acquisition-related expenses, amortization of acquired product technology rights, cost-saving initiatives, contingent consideration costs, legal proceedings expenses, and non-cash interest expense on convertible notes. Amgen also adjusts for the tax effects of these items.

In this report, Amgen defines Free Cash Flow (FCF) as a non-GAAP financial measure calculated by subtracting capital expenditures from cash flow from operations, both as determined in accordance with GAAP. The company presents FCF as an additional measure of its liquidity.